[Propafenone in refractory supraventricular arrhythmias]

Twelve patients with ventricular arrhythmias were given 300-900 mg oral of propafenon daily. We have obtained VT's suppression in 6 of 8 cases (75%) and "complex" VEB's suppression or significant reduction in 6 of 10 cases (60%). Total VEB have been strongly reduced (-91,2%) in 7 of 12 patients (58,3%). The effects of Propafenon on electrocardiographic intervals have not been significant at lower doses and only with 900 mg we have noted a significant (p less than 0,05) lengthening of the P-R (+27,1%) and QTc (+10,2%) intervals. Propafenon has never caused important negative inotropic effects. These results have been confirmed during a follow-up period of 5-19 months. In conclusion we believe that Propafenon must be considered a highly efficient drug for the treatment and prevention of refractory ventricular arrhythmias.